Here are the key catalysts for 3 US biotech stocks into year end
- Investing.com
Pro- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vertex Pharmaceuticals Inc (VRTX)Assess today's live Vertex Pharmaceuticals Inc (VRTX) share price, performance and insights using our live NASDAQ: VRTX stock exchange data.
Analyse the historical data and Vertex Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Vertex share price buy/sell indicators using real-time data (or discuss the Vertex (VRTX) stock price today with other investors in the Vertex NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ VRTX share price (ISIN: US92532F1003) to enhance your trading decisions with our free investment tools and resources.
What Is the Vertex Pharmaceuticals Inc Share Price Today?
The Vertex share price today is 456.97.
What Is the Stock Symbol for Vertex Pharmaceuticals Inc
The stock symbol (or 'ticker') for Vertex Pharmaceuticals Inc is "VRTX."
What Stock Exchange Does Vertex Pharmaceuticals Inc Trade On?
Vertex Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Vertex Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Vertex Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Vertex Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Vertex share price buy/sell indicators using real-time data (or discuss the Vertex (VRTX) stock price today with other investors in the Vertex NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ VRTX share price (ISIN: US92532F1003) to enhance your trading decisions with our free investment tools and resources.
What Is the Vertex Pharmaceuticals Inc Share Price Today?
The Vertex share price today is 456.97.
What Is the Stock Symbol for Vertex Pharmaceuticals Inc
The stock symbol (or 'ticker') for Vertex Pharmaceuticals Inc is "VRTX."
What Stock Exchange Does Vertex Pharmaceuticals Inc Trade On?
Vertex Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Vertex Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Vertex Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
456.97
-8.76(-1.88%)
Closed
After Hours
456.10-0.87(-0.19%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
455.01
468.51
52 wk Range
348.46
519.88
VRTX Scorecard
Full Analysis
9 analysts have revised their earnings downwards for the upcoming period
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
455.01468.51
52 wk Range
348.46519.88
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockVRTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
513.52
Upside
+12.37%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock generally trades with low price volatility
- RBC's top 10 questions and answers on biotech stocks
- Investing.com
- JPMorgan is out with its 2025 outlook for biotech stocks
- Investing.com
Pro
- Here are the key catalysts for 3 US biotech stocks into year end
- Investing.com
Pro - JPMorgan is out with its 2025 outlook for biotech stocks
- Investing.com
Pro - Citi initiates coverage on 5 new biotech stocks
- Investing.com
Vertex Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Inc SWOT Analysis
CF Market Dominance | Explore Vertex's stronghold in cystic fibrosis treatments, driving robust financial performance and fueling expansion into new therapeutic areas |
Pain Management Pionee | Delve into VX-548, Vertex's non-opioid pain therapy under FDA priority review, with potential peak revenue of $5.8 billion |
Diabetes Breakthrough | Learn about VX-880's promising results in Type 1 Diabetes trials, potentially revolutionizing treatment and opening new market opportunities |
Growth Beyond CF | Analysts set price targets ranging from $421 to $535, reflecting optimism about Vertex's diversification strategy and pipeline potential |
VRTX Full Pro Research
Institutional-Grade Stock Analysis
Understand how VRTX earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Compare VRTX to Peers and Sector
Metrics to compare | VRTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVRTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −245.3x | −5.1x | −0.7x | |
PEG Ratio | 2.19 | −0.19 | 0.00 | |
Price/Book | 7.5x | 5.9x | 2.6x | |
Price / LTM Sales | 11.1x | 20.2x | 3.2x | |
Upside (Analyst Target) | 15.2% | 52.1% | 46.4% | |
Fair Value Upside | Unlock | 12.0% | 6.9% | Unlock |
Analysts' Recommendations
22 Buy
11 Hold
3 Sell
Ratings:
30 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 518.33
(+13.43% Upside)
People Also Watch
FAQ
What Is the Vertex (VRTX) Stock Price Today?
The Vertex stock price today is 456.97
What Stock Exchange Does Vertex Trade On?
Vertex is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Vertex?
The stock symbol for Vertex is "VRTX."
What Is the Vertex Market Cap?
As of today, Vertex market cap is 117.68B.
What is Vertex Earnings Per Share?
The Vertex EPS is -1.86.
What Is the Next Vertex Earnings Date?
Vertex will release its next earnings report on 11 Feb 2025.
From a Technical Analysis Perspective, Is VRTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.